Analyst: Multibillion-dollar obesity market estimate could boost Novo trading

A Morgan Stanley analysis foresees the Danish drugmaker taking part of a lucrative weight-loss treatment market in the future, and though a Sydbank analyst has some doubts, he predicts investors are likely to take note.

Photo: Novo Nordisk / Pr

The Novo Nordisk stock could be boosted in Danish trading following a recent Financial Times article, says an analyst at Danish bank Sydbank, Søren Løntoft Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs